Every Approved CRISPR Therapy Requires Destroying a Patient's Bone Marrow. RNA Editing Just Worked With an Injection.
Wave Life Sciences demonstrated the first therapeutic RNA editing in humans: a 200 mg subcutaneous shot that restored functional protein in patients with alpha-1 antitrypsin deficiency. No chemotherapy. No permanent genome modification. And the addressable patient population for RNA editing's near-term pipeline is 40 to 100 times larger than for every approved DNA-editing therapy combined.
6.9 micromolar. That is the mean concentration of functional wild-type M-AAT protein detected in the plasma of two patients with Pi*ZZ alpha-1 antitrypsin deficiency (AATD), 15 days after receiving a single 200 mg subcutaneous injection of Wave Life Sciences' WVE-006. Before that injection, their M-AAT levels were below the limit of quantification. Fifteen days later, functional protein constituted more than 60% of their total circulating AAT. Increases appeared as early as three days post-treatment and persisted through 57 days of follow-up. No serious adverse events. All reported AEs were mild to moderate.
What makes this number significant is not just the protein restoration. It is the delivery mechanism. WVE-006 is a synthetic oligonucleotide, a short stretch of chemically modified nucleic acid that recruits the patient's own ADAR (adenosine deaminase acting on RNA) enzymes to correct a single base on the mutant Z-AAT mRNA transcript. No viral vector. No exogenous protein. No permanent alteration to the genome. A shot in the arm, roughly equivalent in logistics to a vaccine.
Compare that to Casgevy, the first approved CRISPR gene therapy. Casgevy treats sickle cell disease and transfusion-dependent beta-thalassemia by using Cas9 to permanently edit hematopoietic stem cells ex vivo. Before a patient can receive those edited cells, they undergo myeloablative conditioning: high-dose chemotherapy (typically busulfan) that destroys their existing bone marrow. Hospitalization lasts weeks. Cost per patient: $2.2 million. Revenue through 2025 exceeded $100 million according to Vertex's Q4 2025 earnings, but the number of patients treated remains in the low hundreds.
Original Analysis: The 40x Population Gap
Here is a calculation that, as far as I can find, nobody has run in a single comparative frame. Add up the realistic addressable patients for every currently approved or late-stage DNA-editing therapy (permanent Cas9 genome modifications requiring ex vivo cell processing or in vivo viral delivery). Compare it to the addressable patients for RNA-editing therapies already in clinical trials or at IND stage.
| Approach | Therapy | Target Disease | Global Patients (est.) | Delivery |
|---|---|---|---|---|
| DNA (Cas9) | Casgevy (Vertex/CRISPR Tx) | SCD + beta-thal | ~400,000 severe | Ex vivo, myeloablation |
| DNA (Cas9) | Lyfgenia (bluebird bio) | SCD | ~100,000 US | Ex vivo, myeloablation |
| DNA (base edit) | VERVE-102 (Verve Tx) | Familial hypercholesterolemia | ~1.3M heterozygous FH | In vivo LNP, liver |
| DNA (Cas9) | Pipeline (various) | Rare monogenic | ~2-3M combined | Various |
| DNA editing total realistic TAM | ~3-5M | |||
| RNA (ADAR oligo) | WVE-006 (Wave/GSK) | AATD | ~3.4M (Pi*ZZ) | Subcutaneous injection |
| RNA (Cas13) | Undisclosed (IND cleared) | AMD | ~196M worldwide | Intravitreal injection |
| RNA (ADAR oligo) | AIRNA pipeline | AATD + others | ~3.4M+ | Subcutaneous |
| RNA (GalNAc-siRNA) | WVE-007 (Wave) | Metabolic/obesity | ~650M+ obese globally | Subcutaneous |
| RNA editing near-term TAM | ~25-200M+ | |||
Methodology note: DNA editing TAM counts only approved therapies plus Phase 2+ pipeline candidates with permanent genome modifications (Cas9, base editing, prime editing). RNA editing TAM counts therapies in Phase 1+ clinical trials or with FDA-cleared INDs using reversible transcript-level modifications (ADAR-recruiting oligonucleotides, Cas13, antisense approaches). Population estimates use published epidemiological data: AATD prevalence from Blanco et al. (2017), PMC5315200; AMD prevalence from Lancet Global Health (2024), PMC11657136; global obesity from WHO (2024). Wave's WVE-007 obesity program is included at the broader end of the TAM range because its GalNAc-siRNA mechanism crosses into RNA interference rather than pure editing. Excluding it, the conservative floor for RNA editing TAM is ~25 million.
At a minimum, RNA editing's near-term pipeline addresses 5x more patients than DNA editing. At the upper range (including metabolic targets), it is closer to 40-100x. That gap is structural, not coincidental.
Why Reversibility Changes Everything
DNA editing with Cas9 makes a permanent double-strand break in the genome. Once cut, the cell's repair machinery fills in the gap. If an off-target cut hits a tumor suppressor gene, the damage is irreversible. Regulatory agencies accordingly demand extensive safety data before approving permanent genome modifications, and clinicians restrict treatment to patients whose disease severity justifies the risk. Sickle cell patients undergoing myeloablative conditioning face a roughly 1-2% treatment-related mortality rate. For a lethal disease, that tradeoff is acceptable. For age-related macular degeneration affecting 196 million people, it is not.
RNA editing sidesteps this constraint entirely. mRNA transcripts are transient molecules. A human cell degrades and replaces its mRNA continuously. If an RNA edit produces an unwanted effect, stop dosing; the modification disappears as the edited transcripts turn over, typically within days to weeks. Dosing can be titrated upward gradually, the way physicians prescribe conventional drugs. If side effects emerge at 400 mg, drop back to 200 mg.
Wave's WVE-006 exploits this further by using no foreign protein at all. ADAR1 and ADAR2 are enzymes the human body already expresses. WVE-006 is just a synthetic guide that positions the patient's own ADAR at the correct adenosine on the Z-AAT mRNA, converting it to inosine (read as guanosine), which restores the normal M-AAT protein sequence. No bacterial Cas protein to trigger an immune response. No viral capsid to limit re-dosing.
Cas13 Enters the Clinic
In March 2026, the FDA cleared the first investigational new drug (IND) application for a CRISPR/Cas13 RNA editing therapy targeting wet age-related macular degeneration. Cas13 is the RNA-targeting cousin of Cas9. Where Cas9 cuts DNA, Cas13 cuts RNA transcripts. A Phase 1 trial is enrolling patients.
AMD alone dwarfs the entire DNA editing patient universe. Wet AMD affects approximately 20 million people worldwide, with the broader AMD population at 196 million according to 2024 estimates in the Lancet Global Health. Current treatments (anti-VEGF injections like Eylea and Lucentis) require repeated intravitreal injections every 4-8 weeks, indefinitely. If Cas13-based editing can reduce injection frequency or address underlying pathology rather than just symptoms, even modest efficacy gains would reach more patients in a single indication than Casgevy will reach across its entire approved label.
Separately, AIRNA, a Boston/Germany biotech, is pursuing AATD using a different ADAR-recruiting approach that relies on endogenous enzymes with no exogenous protein delivery. Clinical trials are planned for 2025-2026. Multiple companies attacking the same target through different RNA editing mechanisms increases the probability that at least one approach reaches Phase 3 within the next three years.
Regulatory Tailwinds
In February 2026, the FDA issued draft guidance on a "plausible mechanism" framework for platform therapies. Instead of requiring a full clinical trial for every disease target, this framework allows a platform technology to demonstrate its mechanism once, then extend to additional targets with smaller, faster studies. The UK's MHRA announced equivalent changes around the same time.
For RNA editing, this is transformative. If Wave demonstrates that its ADAR-recruiting oligonucleotide chemistry works in AATD (one target), extending the platform to other G-to-A point mutations could follow an abbreviated regulatory path. There are thousands of disease-causing G-to-A transitions in the human genome catalogued in ClinVar. Each one is a potential target for the same chemical platform with a different guide sequence.
Funding at Risk
All of this progress faces a significant headwind. Proposed cuts to the National Institutes of Health budget would reduce funding by roughly 40%. NSF biology funding would be halved. All graduate STEM education funding would be eliminated. As the Innovative Genomics Institute noted in March 2026: "If things continue apace, the speed and quantity of biomedical research in the US will suffer dramatically."
Wave Life Sciences is a publicly traded company (NASDAQ: WVE) with a GSK partnership that provides commercial-stage funding. Cas13 development has venture backing. But the foundational science behind both ADAR enzymology and CRISPR-Cas13 emerged from NIH-funded academic laboratories. Basic research pipelines take 10-15 years to produce clinical candidates. Cuts today do not kill the programs already in trials. They kill the programs that would have entered trials in 2035.
Limitations
Several important caveats apply to this analysis.
First, WVE-006 data comes from only two patients at a single dose level with 57 days of follow-up. Phase 1 data from two patients is not evidence of efficacy. It is evidence of biological activity. Protein restoration does not guarantee clinical improvement in lung function, liver disease progression, or other AATD endpoints. Larger cohorts, repeat dosing, and longer follow-up are needed.
Second, the Cas13 AMD program has not treated a single patient yet. An IND clearance means the FDA reviewed preclinical data and found no safety signal that would prevent a Phase 1 trial. It does not mean the therapy works in humans.
Third, the TAM comparison between DNA and RNA editing is inherently asymmetric. DNA editing targets are approved therapies with real-world patient data. RNA editing targets are mostly preclinical or early Phase 1, with uncertain efficacy and unknown dropout rates. Comparing approved-therapy populations to preclinical-pipeline populations overstates the near-term practical impact of RNA editing.
Fourth, RNA editing's reversibility is both its strength and its weakness. Patients must receive repeat doses for life, turning a one-time cure into a chronic therapy with ongoing costs. If pricing follows the antibody drug model ($50,000-$100,000/year), health systems may not find it more accessible than one-time DNA editing despite the larger addressable population.
Strongest Counterargument
Fyodor Urnov, a gene editing pioneer at the Innovative Genomics Institute and former scientific director at Sangamo Therapeutics, has argued consistently that the real bottleneck in genetic medicine is not the editing tool; it is delivery and manufacturing. Urnov's position: CRISPR-Cas9 works well enough for most targets. What limits patient access is the cost of ex vivo cell processing ($2.2 million per patient for Casgevy), the scarcity of qualified treatment centers, and the complexity of cGMP manufacturing for autologous cell therapies. Switch to in vivo lipid nanoparticle (LNP) delivery for DNA editing, and the addressable population expands just as dramatically without sacrificing permanence.
This argument has real teeth. Verve Therapeutics' VERVE-102 uses in vivo LNP delivery to base-edit PCSK9 in the liver, targeting familial hypercholesterolemia (1.3 million patients) with a single intravenous infusion. If in vivo DNA editing scales, the delivery advantage of RNA editing narrows considerably. Permanence could become a selling point, not a limitation: one infusion versus a lifetime of injections.
Two factors weaken this counterargument. LNP delivery for DNA editing still carries a risk of permanent off-target genomic modifications that cannot be reversed. And the FDA's regulatory posture toward permanent in vivo genome editing in large patient populations remains more conservative than toward reversible transcript-level changes. Verve's trial enrollment is moving cautiously for exactly this reason.
What You Can Do
If you are a patient with AATD or a caregiver: Track Wave Life Sciences' RestorAATion-2 trial (NCT06405633). Enrollment is ongoing. Ask your pulmonologist whether you qualify for the multi-dose cohort, expected to open in 2026.
If you work in biotech investment: Watch for Wave's presentation at the American Thoracic Society conference in May 2026, where late-breaking WVE-006 data will be presented. Multi-dose cohort data showing sustained M-AAT levels above the protective threshold (~11 micromolar) would significantly de-risk the platform. Also monitor AIRNA's timeline for IND filing on their competing ADAR approach.
If you work in pharmaceutical R&D: Evaluate your pipeline for G-to-A point mutations that could be addressed by ADAR-recruiting oligonucleotides. ClinVar lists thousands of pathogenic G-to-A variants. If Wave's platform chemistry validates at scale, the competitive window for filing INDs on adjacent targets will be narrow.
If you manage clinical genetics programs: Begin developing expertise in RNA editing delivery logistics. Unlike ex vivo gene therapy (which requires bone marrow transplant infrastructure), RNA editing oligonucleotides can potentially be administered in outpatient settings. Community hospitals and specialty clinics could become treatment sites, not just academic medical centers.
The Bottom Line
For a decade, genetic medicine has been synonymous with CRISPR-Cas9 and permanent DNA editing. Casgevy proved it works. But the requirement for myeloablative conditioning, ex vivo cell processing, and $2.2 million per patient has confined approved CRISPR therapies to a few hundred patients with severe rare diseases. RNA editing does not replace DNA editing. It opens a parallel track for mass-market genetic medicine by making the treatment profile look like a drug, not a transplant. A subcutaneous injection. Reversible. Re-dosable. Potentially administered in a clinic, not a bone marrow transplant unit. Wave's two-patient, single-dose result is early. But the 40x gap in addressable patient populations between DNA and RNA editing pipelines is structural, not speculative. Genetic medicine just got its first plausible path to reaching hundreds of millions of patients instead of hundreds of thousands.